JP2018523542A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018523542A5 JP2018523542A5 JP2018509502A JP2018509502A JP2018523542A5 JP 2018523542 A5 JP2018523542 A5 JP 2018523542A5 JP 2018509502 A JP2018509502 A JP 2018509502A JP 2018509502 A JP2018509502 A JP 2018509502A JP 2018523542 A5 JP2018523542 A5 JP 2018523542A5
- Authority
- JP
- Japan
- Prior art keywords
- signal
- nerve
- patient
- neural activity
- fibers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000001537 neural effect Effects 0.000 claims description 232
- 210000001186 vagus nerve Anatomy 0.000 claims description 192
- 210000005036 nerve Anatomy 0.000 claims description 190
- 239000000835 fiber Substances 0.000 claims description 176
- 206010006482 Bronchospasm Diseases 0.000 claims description 108
- 230000007885 bronchoconstriction Effects 0.000 claims description 95
- 230000000638 stimulation Effects 0.000 claims description 90
- 230000036982 action potential Effects 0.000 claims description 82
- 230000000694 effects Effects 0.000 claims description 66
- 230000001965 increasing effect Effects 0.000 claims description 55
- 238000011282 treatment Methods 0.000 claims description 55
- 230000033228 biological regulation Effects 0.000 claims description 47
- 210000004072 lung Anatomy 0.000 claims description 44
- 210000004369 blood Anatomy 0.000 claims description 35
- 239000008280 blood Substances 0.000 claims description 35
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 34
- 230000008035 nerve activity Effects 0.000 claims description 33
- 210000005091 airway smooth muscle Anatomy 0.000 claims description 32
- 230000001734 parasympathetic effect Effects 0.000 claims description 23
- 229910052760 oxygen Inorganic materials 0.000 claims description 21
- 230000036387 respiratory rate Effects 0.000 claims description 21
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 19
- 239000001301 oxygen Substances 0.000 claims description 19
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 17
- 230000003247 decreasing effect Effects 0.000 claims description 16
- 239000001569 carbon dioxide Substances 0.000 claims description 15
- 230000002889 sympathetic effect Effects 0.000 claims description 15
- 230000007423 decrease Effects 0.000 claims description 12
- 238000001514 detection method Methods 0.000 claims description 12
- 238000002513 implantation Methods 0.000 claims description 9
- 230000006461 physiological response Effects 0.000 claims description 7
- 230000001052 transient effect Effects 0.000 claims description 7
- 230000036961 partial effect Effects 0.000 claims description 5
- 230000009467 reduction Effects 0.000 claims description 3
- 238000000034 method Methods 0.000 description 107
- 229940124630 bronchodilator Drugs 0.000 description 79
- 208000006673 asthma Diseases 0.000 description 43
- 230000003227 neuromodulating effect Effects 0.000 description 43
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 32
- 210000004126 nerve fiber Anatomy 0.000 description 29
- 230000004936 stimulating effect Effects 0.000 description 27
- 230000008602 contraction Effects 0.000 description 23
- 230000001105 regulatory effect Effects 0.000 description 22
- 210000001170 unmyelinated nerve fiber Anatomy 0.000 description 22
- 230000003287 optical effect Effects 0.000 description 16
- 230000004044 response Effects 0.000 description 15
- 230000001515 vagal effect Effects 0.000 description 15
- 239000000168 bronchodilator agent Substances 0.000 description 14
- 230000029058 respiratory gaseous exchange Effects 0.000 description 14
- 210000003437 trachea Anatomy 0.000 description 14
- 208000009079 Bronchial Spasm Diseases 0.000 description 13
- 241000700159 Rattus Species 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 12
- 230000011664 signaling Effects 0.000 description 12
- 229930003347 Atropine Natural products 0.000 description 11
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 11
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 11
- 229960000396 atropine Drugs 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 208000014181 Bronchial disease Diseases 0.000 description 10
- 239000000808 adrenergic beta-agonist Substances 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 238000002560 therapeutic procedure Methods 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 230000001078 anti-cholinergic effect Effects 0.000 description 9
- 230000001066 destructive effect Effects 0.000 description 9
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 8
- 229960002052 salbutamol Drugs 0.000 description 8
- 230000007781 signaling event Effects 0.000 description 8
- 238000004891 communication Methods 0.000 description 7
- 239000013078 crystal Substances 0.000 description 7
- 230000002685 pulmonary effect Effects 0.000 description 7
- 230000008859 change Effects 0.000 description 6
- 239000002131 composite material Substances 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 230000000763 evoking effect Effects 0.000 description 6
- 239000002858 neurotransmitter agent Substances 0.000 description 6
- 230000011514 reflex Effects 0.000 description 6
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- 244000025254 Cannabis sativa Species 0.000 description 5
- 208000005279 Status Asthmaticus Diseases 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 210000001715 carotid artery Anatomy 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000012544 monitoring process Methods 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 230000004007 neuromodulation Effects 0.000 description 5
- 230000000241 respiratory effect Effects 0.000 description 5
- 210000002460 smooth muscle Anatomy 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 230000002301 combined effect Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 230000010339 dilation Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000007372 neural signaling Effects 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 238000011321 prophylaxis Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000001953 sensory effect Effects 0.000 description 4
- 208000003098 Ganglion Cysts Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000005400 Synovial Cyst Diseases 0.000 description 3
- 238000002679 ablation Methods 0.000 description 3
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
- 229960004373 acetylcholine Drugs 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 210000003792 cranial nerve Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000003434 inspiratory effect Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000013222 sprague-dawley male rat Methods 0.000 description 3
- 238000012453 sprague-dawley rat model Methods 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- 206010003497 Asphyxia Diseases 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010021118 Hypotonia Diseases 0.000 description 2
- 239000012839 Krebs-Henseleit buffer Substances 0.000 description 2
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 2
- 229910021607 Silver chloride Inorganic materials 0.000 description 2
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 description 2
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 230000002638 denervation Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000030214 innervation Effects 0.000 description 2
- 210000000867 larynx Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000036640 muscle relaxation Effects 0.000 description 2
- 230000007383 nerve stimulation Effects 0.000 description 2
- 238000007427 paired t-test Methods 0.000 description 2
- 210000005037 parasympathetic nerve Anatomy 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 210000002416 recurrent laryngeal nerve Anatomy 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000021 stimulant Substances 0.000 description 2
- 210000003270 subclavian artery Anatomy 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000009284 tracheal contraction Effects 0.000 description 2
- 230000007384 vagal nerve stimulation Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020853 Hypertonic bladder Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 238000011292 agonist therapy Methods 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001022 anti-muscarinic effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000007883 bronchodilation Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013479 data entry Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- HRLIOXLXPOHXTA-NSHDSACASA-N dexmedetomidine Chemical compound C1([C@@H](C)C=2C(=C(C)C=CC=2)C)=CN=C[N]1 HRLIOXLXPOHXTA-NSHDSACASA-N 0.000 description 1
- 229960004253 dexmedetomidine Drugs 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- 238000004868 gas analysis Methods 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 210000003801 laryngeal nerve Anatomy 0.000 description 1
- WABPQHHGFIMREM-UHFFFAOYSA-N lead(0) Chemical compound [Pb] WABPQHHGFIMREM-UHFFFAOYSA-N 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000020629 overactive bladder Diseases 0.000 description 1
- 210000001002 parasympathetic nervous system Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000273 spinal nerve root Anatomy 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008625 synaptic signaling Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562208057P | 2015-08-21 | 2015-08-21 | |
| US62/208,057 | 2015-08-21 | ||
| PCT/IB2016/054957 WO2017033101A1 (en) | 2015-08-21 | 2016-08-18 | Neuromodulation device |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018523542A JP2018523542A (ja) | 2018-08-23 |
| JP2018523542A5 true JP2018523542A5 (cg-RX-API-DMAC7.html) | 2021-02-04 |
Family
ID=56853696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018509502A Pending JP2018523542A (ja) | 2015-08-21 | 2016-08-18 | 神経調節デバイス |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11878160B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3337556B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2018523542A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20180044941A (cg-RX-API-DMAC7.html) |
| CN (1) | CN108367151A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016310626A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112018003107A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2996252A1 (cg-RX-API-DMAC7.html) |
| ES (2) | ES2982192T3 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2018105336A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017033101A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11571574B2 (en) | 2016-11-11 | 2023-02-07 | Galvani Bioelectronics Limited | Treatment of diseases mediated by thyroid and parathyroid hormones |
| CN109045468B (zh) * | 2018-08-09 | 2022-05-24 | 西安科悦医疗技术有限公司 | 一种耳部迷走神经刺激系统及其装置 |
| EP4093500A4 (en) * | 2020-01-23 | 2024-06-05 | Saluda Medical Pty Ltd | NEUROMODULATION OF PRIMARY AND/OR POSTSYNAPTICAL NEURONS |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993002744A1 (en) | 1991-08-09 | 1993-02-18 | Cyberonics, Inc. | Treatment of anxiety disorders by nerve stimulation |
| EP1833559B1 (en) * | 2004-12-27 | 2010-11-24 | The Feinstein Institute for Medical Research | Treating inflammatory disorders by electrical vagus nerve stimulation |
| US8660647B2 (en) * | 2005-07-28 | 2014-02-25 | Cyberonics, Inc. | Stimulating cranial nerve to treat pulmonary disorder |
| US8812112B2 (en) * | 2005-11-10 | 2014-08-19 | ElectroCore, LLC | Electrical treatment of bronchial constriction |
| US8874227B2 (en) * | 2009-03-20 | 2014-10-28 | ElectroCore, LLC | Devices and methods for non-invasive capacitive electrical stimulation and their use for vagus nerve stimulation on the neck of a patient |
| CN101674862A (zh) * | 2005-11-10 | 2010-03-17 | 电子核心公司 | 支气管收缩的电刺激治疗 |
| US20100217347A1 (en) * | 2006-12-16 | 2010-08-26 | Greatbatch, Inc. | Neurostimulation for the treatment of pulmonary disorders |
| US8483831B1 (en) * | 2008-02-15 | 2013-07-09 | Holaira, Inc. | System and method for bronchial dilation |
| CA2723806C (en) * | 2008-05-09 | 2022-05-31 | Innovative Pulmonary Solutions, Inc. | Systems, assemblies, and methods for treating a bronchial tree |
| US8843210B2 (en) * | 2009-03-20 | 2014-09-23 | ElectroCore, LLC | Non-invasive vagal nerve stimulation to treat disorders |
| US20120302909A1 (en) * | 2009-11-11 | 2012-11-29 | Mayse Martin L | Methods and systems for screening subjects |
| US9398933B2 (en) | 2012-12-27 | 2016-07-26 | Holaira, Inc. | Methods for improving drug efficacy including a combination of drug administration and nerve modulation |
| JP2015008746A (ja) * | 2013-06-26 | 2015-01-19 | オリンパス株式会社 | 神経刺激装置、副作用予測装置および神経刺激装置の作動方法 |
| US10413731B2 (en) | 2014-01-17 | 2019-09-17 | Cardiac Pacemakers, Inc. | Selective nerve stimulation using presynaptic terminal depletion block |
| US9737716B2 (en) * | 2014-08-12 | 2017-08-22 | Cyberonics, Inc. | Vagus nerve and carotid baroreceptor stimulation system |
-
2016
- 2016-08-18 BR BR112018003107A patent/BR112018003107A2/pt not_active Application Discontinuation
- 2016-08-18 JP JP2018509502A patent/JP2018523542A/ja active Pending
- 2016-08-18 ES ES22169569T patent/ES2982192T3/es active Active
- 2016-08-18 KR KR1020187007903A patent/KR20180044941A/ko not_active Withdrawn
- 2016-08-18 AU AU2016310626A patent/AU2016310626A1/en not_active Abandoned
- 2016-08-18 CN CN201680061734.8A patent/CN108367151A/zh active Pending
- 2016-08-18 ES ES16760189T patent/ES2914685T3/es active Active
- 2016-08-18 EP EP16760189.7A patent/EP3337556B1/en active Active
- 2016-08-18 EP EP22169569.5A patent/EP4052756B1/en active Active
- 2016-08-18 WO PCT/IB2016/054957 patent/WO2017033101A1/en not_active Ceased
- 2016-08-18 CA CA2996252A patent/CA2996252A1/en not_active Abandoned
- 2016-08-18 US US15/752,502 patent/US11878160B2/en active Active
- 2016-08-18 RU RU2018105336A patent/RU2018105336A/ru not_active Application Discontinuation
-
2023
- 2023-12-12 US US18/537,151 patent/US20240131327A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7520800B2 (ja) | 呼吸機能を可能にするために脊髄ネットワークにアクセスすること | |
| EP4299106B1 (en) | Accessing spinal network to enable respiratory function | |
| US20240131327A1 (en) | Neuromodulation Device | |
| EP3261711B1 (en) | Neuromodulation device | |
| US11147971B2 (en) | Systems methods and devices for closed loop stimulation to enhance stroke recovery | |
| JP2019506960A (ja) | 神経調整デバイス | |
| JP2018523542A5 (cg-RX-API-DMAC7.html) | ||
| US20200086109A1 (en) | Neuromodulation device | |
| Sabetian et al. | Optimizing a novel nerve cuff electrode to record bidirectional neural activity | |
| EP4635557A1 (en) | System for inhibiting action potential conduction in a nerve | |
| PODBREGAR et al. | Frequency dependent effect of selective biphasic left vagus nerve stimulation on heart rate and arterial pressure | |
| Fisher et al. | Blocking Central Pathways in the Primate Motor | |
| Reier | Plasticity and Activation of Spared Intraspinal Respiratory Circuits Following Spinal Cord Injury | |
| HK40018951B (en) | Accessing spinal network to enable respiratory function | |
| HK40018951A (en) | Accessing spinal network to enable respiratory function |